抗HER2 癌症特定的mAb,H2Mab-250-hG1,具有比特拉斯图祖马布更高的补充依赖细胞毒性
Hiroyuki Suzuki1, Tomokazu Ohishi2,3, Tomohiro Tanaka1
1Department of Antibody Drug Development, Tohoku University Graduate School of Medicine, 2-1 Seiryo-machi, Aoba-ku, Sendai 980-8575, Japan.
International journal of molecular sciences
|August 10, 2024
概括
一种新的癌症特异性抗体H2Mab-250显示出对抗HER2阳性乳腺癌有前途的抗瘤作用. 与特拉斯图祖马布相比,它表现出优异的补充依赖性细胞毒性 (CDC),这表明了新的治疗策略.
科学领域:
- 免疫学 免疫学 免疫学
- 在瘤学瘤学.
- 生物技术是生物技术.
背景情况:
- 癌症特异性单克隆抗体 (CasMabs) 提供有针对性的治疗,并减少副作用.
- H2Mab-250是一种新的CasMab,针对人类表皮生长因子受体2 (HER2) 阳性癌症.
- 与trastuzumab不同的是,H2Mab-250对HER2阳性癌细胞具有特异性.
研究的目的:
- 为了比较H2Mab-250-hG1和trastuzumab的抗体依赖细胞细胞毒性 (ADCC) 和补充依赖细胞细胞毒性 (CDC).
- 评估H2Mab-250-hG1在HER2阳性乳腺癌中的治疗潜力.
主要方法:
- 使用流细胞计和免疫组织化学来评估抗体反应性.
- 使用HER2过度表达细胞系和人类自然杀手细胞进行了ADCC和CDC测定.
- 在体内抗瘤疗效在乳腺癌移植中进行了评估.
主要成果:
- H2Mab-250-hG1对HER2阳性癌细胞表现出特定的结合,节省了正常细胞.
- 无论是H2Mab-250-hG1还是trastuzumab都显示出ADCC活性,而trastuzumab的效果略高.
- H2Mab-250-hG1显示出与特拉斯图祖马布相比显著优越的CDC活性.
结论:
- H2Mab-250-hG1具有明显的细胞毒性机制,在CDC中具有显著的优势.
- 这些发现支持对H2Mab-250-hG1用于HER2阳性瘤的进一步临床开发.
- H2Mab-250代表了对现有针对HER2的治疗方法的有希望的替代方案或补充.
更多相关视频
13:19Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery
Published on: April 26, 2024
2.6K
11:02Genetic Encoding of a Non-Canonical Amino Acid for the Generation of Antibody-Drug Conjugates Through a Fast Bioorthogonal Reaction
Published on: September 14, 2018
7.7K
相关概念视频
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:31Hybridoma Technology
14.2K
Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
14.2K